china-biotech
(2)
CORXEL Pharmaceuticals
CORXEL Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies for cardiometabolic diseases worldwide. Spun out of RTW Investments in 2019 (formerly JiXing Pharmaceuticals) and dual-based in Berkeley Heights, New Jersey and Shanghai, CORXEL is advancing a pipeline led by CX11, a differentiated oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, alongside JX10 for acute ischemic stroke and JX09 for hypertension. In January 2026 the company raised up to $287 million in Series D1 financing to push these programs through late-stage clinical trials.
Sandy Mou
Sandy Mou, MD, is the Chief Executive Officer and Board Executive Director of CORXEL Pharmaceuticals, a New Jersey- and Shanghai-linked biotech developing an oral small molecule GLP-1 receptor agonist for obesity and diabetes. A Fudan-trained clinician turned pharma executive with nearly three decades at GSK, AstraZeneca, Johnson & Johnson, and MSD, she led MSD China's oncology unit into the country's top three within three years and later took Shanghai Allist public on the STAR Market before joining JIXING - now CORXEL - in early 2023.